Clinical Trial Update: CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing Campath-Tacrolimus vs IL2R monoclonal antibody/Tacrolimus/MMF in renal transplantation has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• CamTac (alemtuzumab plus tacrolimus)
• Campath-Tacrolimus (alemtuzumab with tacrolimus)
• IL2R monoclonal antibody/Tacrolimus/MMF (daclizumab or basiliximab with tacrolimus and mycophenolate mofetil)

Snippet

Sponsor: EMagnusson | Conditions: Kidney Transplantation, Kidney Diseases | Phase 4 | Status: COMPLETED | Results posted: 2021-09-29